asciminib + dasatinib + prednisone + methotrexate (SWOG Cancer Research Network)

This combination regimen is utilized during the induction phase of the SWOG S2106 clinical trial for patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The regimen consists of four primary components: **asciminib**, a first-in-class STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor; **dasatinib**, a second-generation BCR-ABL1 tyrosine kinase inhibitor (TKI); **prednisone**, a corticosteroid; and **methotrexate**, an antimetabolite. The therapeutic strategy employs dual inhibition of the BCR-ABL1 oncoprotein by targeting both the ATP-binding site (via dasatinib) and the myristoyl pocket (via asciminib), which is intended to overcome resistance and achieve deeper molecular responses. Prednisone and methotrexate provide standard lymphocytotoxic and antimetabolic effects, with methotrexate often administered intrathecally for central nervous system prophylaxis.

Other names

induction phase-SWOG Cancer Research Network-acute lymphoblastic leukemia (Philadelphia chromosome-positive)Induction Phase (SWOG S2106)S2106 Induction RegimenS-2106 Induction RegimenS 2106 Induction Regimen